Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Salus receives SBIR grant for cystic fibrosis research

Oct. 10, 2000

AxyS selects lead compound in asthma program

Oct. 10, 2000

R&D at Darwin Discovery leads to new group of PDE4/TNF inhibitors

Oct. 6, 2000

Phase III trial of Actimmune begins for treatment of idiopathic pulmonary fibrosis

Oct. 6, 2000

New cyclic amide compounds synthesized at Japanese lab act as selective M3 antagonists

Oct. 5, 2000

Cathepsin inhibitors claimed by AstraZeneca for use in COPD

Oct. 5, 2000

FDA approves breath-activated device with corticosteroid for asthma

Oct. 5, 2000

Novel IL-5 biosynthesis inhibitor R-146225 profiled at recent inflammation meeting

Oct. 4, 2000

Inspire submits IND for new cystic fibrosis treatment

Oct. 4, 2000

Selectin inhibitor OC-229-648 chosen for further evaluation in COPD and asthma

Oct. 4, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.